Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics, Inc. - Common Stock
(NQ:
DYN
)
16.89
-0.19 (-1.14%)
Streaming Delayed Price
Updated: 10:24 AM EDT, Oct 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dyne Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
October 06, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
October 02, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
September 29, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
August 27, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
August 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
August 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
August 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN
August 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
August 04, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
August 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
July 28, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
July 02, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
June 30, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
June 30, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
June 30, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 30, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 26, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 25, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 24, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYN
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 20, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today